Abstract：Objective To explore the clinical effect and safety of Danhong injection in the early treatment of senile cerebral infarction. Methods A total of 97 elderly patients with cerebral infarction （admitted from April 2021 to January 2024） at Guanlin hospital of Yixing were divided into two groups by the odd-even method. The control group was treated with edaravone， while the study group was additionally given Danhong injection. The clinical effects， adverse reactions， hemorheological indicators， inflammatory factors and neurological function were compared between the two groups. Results The clinical efficacy rate in the study group was significantly higher than that in the control group （χ2＝5.041， P＝0.025）. The incidence of adverse reactions was not significantly different between the two groups (χ2＝0.801， P＝0.371). After treatment， the levels of hematological indicators， inflammatory factors， and neurological function scores in the study group had significantly lower than in the control group （t＝29.595， 7.606， 16.022， 11.418， 24.454， 26.525， 70.287; all P＜0.05）. Conclusion Danhong injection effectively improves the clinical outcome of elderly patients with cerebral infarction， with high safety. It promotes the improvement of hematological indicators， inflammatory factors， and neurological function.